Shots:
JCR Pharmaceuticals & Modalis have reported successful validation of initial PoC to develop gene therapy targeting CNS disease and will advance to the next phase under a new joint agreement
The new agreement aims at conducting preclinical studies for gene therapy using JCR's BBB-crossing J-Brain Cargo tech and for gene therapy payload using Modalis' CRISPR-GNDM…
NEWS
Shots:
The NMPA has granted approval to Vyloy + fluoropyrimidine & Pt-based CT as a 1L treatment of locally advanced unresectable or metastatic HER2-, CLDN18.2+ G/GEJ adenocarcinoma
Approval was supported by P-III (GLOW: n=145 & SPOTLIGHT: n=36) studies assessing Vyloy + CAPOX & mFOLFOX6, respectively, vs PBO among Chinese patients with this indication
…
Shots:
Atavistik Bio has signed a research collaboration with Pfizer to discover novel precision allosteric therapies for significant unmet medical needs
As per the terms, Atavistik Bio will identify allosteric binders for Pfizer’s 2 undisclosed targets, with Pfizer having the option to license the programs post research. Financial terms are undisclosed
The alliance…
Shots:
Pharmanovia has signed an exclusive in-licensing agreement with Radius Health for abaloparatide (US brand name: Tymlos) to treat osteoporosis, expanding its osteoporosis franchise
Pharmanovia will handle clinical, regulatory & commercial responsibilities across APAC region (China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau & Philippines), while Radius will get an upfront, regulatory…
Shots:
The NMPA has approved Nucala as an add-on therapy with intranasal corticosteroids in CRSwNP adults with inadequately controlled disease. It is approved for patients (≥12yrs.) as an add-on treatment of severe eosinophilic asthma & for adults having eosinophilic granulomatosis with polyangiitis
Approval was based on 2 P-III studies: MERIT assessing Nucala vs PBO…
Shots:
The NMPA has approved iReach Omnia for market release, enhancing precision and access in complex laparoscopic surgeries
The iReach Omnia transforms surgical stapling with 90° articulation, offering precision and maneuverability in confined spaces. It minimizes staple line weak points, reduces anastomotic leakage risks & enhances outcomes in complex procedures like colorectal and thoracic…
Shots:
Hanx Biopharmaceuticals has dosed the first patient with HX044 under its P-I clinical evaluation for treating solid tumors
The dose escalation & expansion P-I/IIa (HX044-I-01) trial will assess safety, tolerability, PK profile & initial efficacy of HX044 for the treatment of advanced solid tumor malignancies
HX044 is a first-in-class bispecific antibody and…
Shots:
The NMPA has approved another NDA of Dovbleron (ROS1 tyrosine kinase inhibitor) for treating locally advanced or metastatic ROS1+ NSCLC. It was approved for those with ROS1+ NSCLC previously treated with ROS1 TKIs in Dec 2024
The approval was supported by pivotal P-II (TRUST-I) study assessing safety, tolerability and efficacy of Dovbleron to…
Shots:
PettureX has reported the launch of its AI-based health scanning app, PettureX App, available through app stores in Jan 20, 2025, to enhance pet health monitoring
The app enables pet owners detect health issues early through guided smartphone image scans of eyes, skin, or teeth. The AI provides real-time assessments and care recommendations,…
Shots:
Chimerix has submitted the NDA of dordaviprone (small molecule imipridone targeting the mitochondrial protease ClpP & dopamine receptor D2) to the US FDA, seeking accelerated approval for treating recurrent H3 K27M-mutant diffuse glioma
Chimerix has also requested priority review along with a Rare Paediatric Disease PRV as a part of submission, as the…

